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Abstract
This review will discuss some issues related to the risk/benefit profile of the use of dietary
antioxidants. Thus, recent progress regarding the potential benefit of dietary antioxidants in the
treatment of chronic diseases with a special focus on immune system and neurodegenerative
disorders will be discussed here. It is well established that reactive oxygen species (ROS) play an
important role in the etiology of numerous diseases, such as atherosclerosis, diabetes and cancer.
Among the physiological defense system of the cell, the relevance of antioxidant molecules, such
as glutathione and vitamins is quite well established. Recently, the interest of researchers has, for
example, been conveyed on antioxidant enzyme systems, such as the heme oxygenase/biliverdin
reductase system, which appears modulated by dietary antioxidant molecules, including
polyphenols and beta-carotene. These systems possibly counteract oxidative damage very
efficiently and finally modulate the activity of oxidative phenomena occurring, for instance, during
pathophysiological processes. Although evidence shows that antioxidant treatment results in
cytoprotection, the potential clinical benefit deriving from both nutritional and supplemental
antioxidants is still under wide debate. In this line, the inappropriate assumption of some lipophylic
vitamins has been associated with increased incidence of cancer rather than with beneficial effects.
Introduction
The term "free radicals" designates a family of compounds
characterized by great reactivity due to the impaired elec-
tron in the outer orbital. To this group belong reactive
oxygen species (ROS), such as superoxide anion, hydroxyl
radical and hydrogen peroxide, as well as reactive nitrogen
species (RNS) which include nitric oxide and peroxyni-
trite. Although structurally different, free radicals share
similar mechanisms to harm body's cells and tissues
through damage on proteins, DNA and lipids [1]. The
alterations of membrane functions occurring as a conse-
quence of phospholipid modifications represent a rele-
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vant, radical species-dependent injury, either when
considering the organism as a whole, or a specific inte-
grated function, such as the immune response [2]. The
potential therapeutic applications of antioxidants in free
radical-related diseases led to the hypothesis of their use
to slow down or reverse, for example, symptoms associ-
ated with with neurodegenerative disorders, such as
Alzheimer's disease (AD), Parkinson's disease (PD), or
spongiform encephalopathies. Such effect could occur
through a block of proinflammatory cytokines action and
the resulting oxidative damage [3-7]. However, several
clinical studies demonstrated that not only malnutrition,
but also the excess of certain nutrients (e.g. iron, alpha-
tocopherol, beta-carotene, ascorbic acid) may set into
motion oxidation phenomena and, therefore, cell injury
[8,9]. Thus, it is of relevance that prior to considering
introducing antioxidant therapy into mainstream medi-
cine, significant advances in basic cell biology, pharma-
cology and clinical bioanalysis will be required.
Oxidative Stress
The body is normally under a dynamic equilibrium
between free radical generation and quenching. The phys-
iological defense systems to counteract free radicals
encompass endogenous enzyme systems, such as catalase,
glutathione reductase and superoxide dismutase, as well
as glutathione, urate and coenzyme Q, or exogenous fac-
tors (β-carotene, vitamin C, vitamin E and selenium) [10].
All these molecules have an antioxidant effect due to their
ability to transform ROS into stable and harmless com-
pounds or by scavenging both ROS and RNS with a redox-
based mechanism [10]. Very recently, a main role in the
fight against oxidative stress has been assumed by
enzymes such as heme oxygenase (HO) and biliverdin
reductase (BVR). Heme oxygenase is a microsomal
enzyme which metabolizes heme into ferrous iron, car-
bon monoxide and biliverdin (BV); the latter is then
reduced by BVR into bilirubin (BR), a molecule endowed
with strong antioxidant and antinitrosative activities [11-
14]. Interestingly, all these protective factors act in a con-
certed way, enhancing the antioxidant defense system of
the cell. When the balance between ROS/RNS and antioxi-
dants turns in favor of the former, oxidative/nitrosative
stress occurs. Although oxidative stress is associated with
most diseases, routine assay methods are not nowadays
available in the clinical practice. A strategy widely used to
determine oxidative stress is measurement of malonyldi-
aldehyde, F2-isoprostanes, or 8-hydroxydesoxyguanosine.
Actually, these molecules are regarded as the most reliable
markers available [15]. A classic example of an oxidation
product apparently leading to disease, is oxidized choles-
terol in low-density lipoprotein (LDL), which displays a
higher atherogenic potential than native LDL, and mainly
involved in the pathogenesis of atherosclerosis and coro-
nary heart disease (CHD) [16].
At the cellular level, a large body of data clearly demon-
strated that ROS, when produced in low amounts and in
a controlled manner, are physiological components of the
signalling generated by cytokines, growth factors and neu-
rotrophic peptides [17-22], although they may also acti-
vate apoptotic cell death [23]. Extracellularly generated
ROS can diffuse through anion channels into the cyto-
plasm; the resulting variation in the cell redox state leads
to modulation of an array of transcription factors (eg. NF-
kB, AP-1), protein kinases (e.g. AKT, JNK, p38), and recep-
tor activated MAP kinases involved in apoptosis [17,24-
26]. Moreover, the proapoptotic molecules Fas and Fas
ligand (FasL) undergo positive transcriptional regulation
after exposure to oxidants [27]. Interestingly, Krammer
and Colleagues demonstrated that in vitro administration
of vitamin E suppresses FasL mRNA expression and pro-
tects T cells of HIV-1 infected individuals from Fas medi-
ated apoptosis [28]. Moreover, it was demonstrated that
administration of combinations of vitamin E and C to cul-
tures of human umbilical vein endothelial cells (HUVEC)
treated with lipopolysaccharide could prevent apoptosis
by upregulation of Bcl-2 [29].
Antioxidants, The Immune System And Related Disorders
The protective function against external pathogens carried
out by the immune system is by itself a source of ROS,
since activated neutrophils, produce free radicals to a sig-
nificant extent [30]. Moreover, during the inflammatory
process, activation of phagocytes through the interaction
of proinflammatory mediators, or bacterial products with
specific receptors results in the assembly of the multicom-
ponent flavoprotein NADPH oxidase which catalyzes the
production of large quantities of the superoxide anion
radical (O2 
-) [31]. In addition to classical reactive oxygen
metabolites, activated neutrophils and monocytes release
the hemoprotein myeloperoxidase (MPO) into the extra-
cellular space, where it catalyzes the oxidation of Cl- by
H2O2 to yield hypochlorous acid (HClO) [32]. HClO is a
non-specific oxidizing and chlorinating agent that reacts
rapidly with a variety of biological compounds, such as
sulphydryls, polyunsatured fatty acids, DNA, pyridine
nucleotides, aliphatic and aromatic aminoacids and nitro-
gen-containing compounds [33-35]. Moreover, apart
from their direct toxic effects, neutrophil-derived oxidants
may promote tissue injury indirectly by altering the pro-
tease/antiprotease equilibrium that normally exists within
the intestinal interstitium. The oxidative inactivation of
important protease inhibitors, coupled to the oxidant-
mediated activation of latent proteases, creates a favorable
environment for neutrophils that allows degradation of
the interstitial matrix through elastases, collagenases and
gelatinases, as well as injury to epithelial cells [36,37].
However, not only immune cell produce ROS necessary
for the microbicidal activity, but they are also sensitive to
external ROS, due to their high polyunsaturated fattyNutrition Journal 2008, 7:29 http://www.nutritionj.com/content/7/1/29
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acids (PUFA) content. Immune cells are atypical, as com-
pared with other somatic cells, in that they contain high
levels of antioxidant vitamins, presumably providing pro-
tection against lipid peroxidation and immunosuppres-
sion, both of which are well known risks posed by high
PUFA content [38]. The reactivity of immune cells to exog-
enous ROS has been shown to be age-dependent. In fact,
lymphocytes from elderly individuals appear to be more
sensitive to exposure to hydrogen peroxide than those
from young adults [39]. Moreover, it has been demon-
strated that a micronutrient deficiency can be the cause of
suppression of immune function affecting both innate T-
cell-mediated immune response and adaptive antibody
response, thus altering the balanced host response. There-
fore, an adequate intake of vitamins and antioxidant ele-
ments seems to be essential for an efficient function of the
immune system. Micronutrient deficiency occurs in vari-
ous conditions, such as eating disorders, tobacco smokers,
chronic diseases, aging. During aging, changes in the
immune system are frequent and associated with
increased susceptibility to infections. Antioxidant vita-
mins and trace elements contribute to maintain an effec-
tive immune response [40]. For example, administration
of vitamin E supplement to healthy elderly patients pro-
duced an increased antibody titer to both hepatitis B and
tetanus vaccine [41], thus enhancing T-cell mediated func-
tions. In conclusion, maintaining adequate antioxidant
status may provide a useful approach in attenuating cell
injury and dysfunction observed in some inflammatory/
autoimmune disorders [42,43].
Autoimmunity has been for decades considered the result
of a breakdown in self-tolerance. At the present, it is
known that autoimmunity is a physiological process [44].
This phenomenon becomes pathological when the
number of autoreactive cells, and particularly the avidity
of their receptors for autoantigens, increases [44]. Trigger-
ing of the disease usually depends both on the increase in
immunogenicity of the target cell, which may be second-
ary to a viral infection (Chediak-Higashi syndrome and
Griscelli syndrome by EBV), and on the individual's own
capacity to recognize the autoantigens (HLA, or T cell rep-
ertoire in Familial hemophagocytic lymphohistiocytosis
[FHL]) [45]. Moreover, apart from the genetic defects that
may predispose to autoimmune diseases, one must take
into account the environmental factors that are implicated
in the development of such pathologies. Among them, an
important role is played by xenobiotics such as chemicals,
drugs and metals [46]. Iron, aluminum, and manganese
readily cross the blood brain barrier via specific or non-
specific carriers, and contribute to the nervous tissue dam-
age [47,48]. The toxic effects of metals are mediated
through free radical formation, or enzyme inhibition [49-
53]. In addition, metals may act as immunosuppressants
(cytostatically), or as immunoadjuvants (through non-
specific activation of the immune response) [54,55]. Sev-
eral mechanisms are proposed on how metals may act
within the immune system to induce autoimmunity.
Patients suffering from scleroderma develop autoantigens
with metal-binding sites. After metal binding, free radical
species are generated which fragment auto-antigens
thereby exposing cryptic epitopes, which may then trigger
autoimmunity [56,57]. Taken together, these findings
underlie the importance of exogenous factors in the
pathogenesis of autoimmunity. Nevertheless, all these ele-
ments do not appear sufficient to provoke chronic autoim-
mune diseases such as Multiple Slerosis (MS), myasthenia
gravis, Insulin Dependent Diabetes Mellitus (IDDM) or
Hashimoto's thyroiditis, and the passage to chronic dis-
ease is usually secondary to a defect in immunoregula-
tion.
Several classes of regulatory T cells, such as Th2, CD25+
and natural killer (NK) T cells, are implied in autoim-
mune pathologies. In an animal model of a Th2-domi-
nated autoimmune syndrome, the administration of the
antioxidant N-acetyl-cysteine (NAC) induced a decrease
in mast-cell expression of both IgE and IL-4 [58]. Of major
interest is the discovery of the therapeutic potential of a
new benzoquinone-containing product derived from
wheat germ fermentation. This latter has been shown to
have immune restorative properties because it affects the
Th1/Th2 network by inhibiting the Th2 response [59].
Another beneficial effect of this molecule is its anti-meta-
static activity, shown in various human malignancies and
Jurkat leukemia cell line [60]. Intriguingly, the combined
treatment with wheat germ and vitamin C profoundly
inhibited metastasis formation in various tumor models
of different origin (Lewis lung carcinoma, B16 melanoma
and human colon carcinoma xenografts [HCR25]) [61].
On the contrary, wheat germ had no toxicity on peripheral
blood leukocytes (PBLs) at doses that affected tumor cells.
The crude powder extract of fermented wheat germ inhib-
its nucleic acid ribose synthesis primarily through the
non-oxidative steps of the pentose cycle [60]. Curiously,
another quinone compound, carnosic acid quinone, like
wheat germ, recovers potent antioxidant activity upon
standing [62].
Keeping in mind the importance of oxidative stress in the
regulation/dysregulation of immune system, the use of
antioxidants in such diseases has been reasonably pro-
posed. Rheumatoid arthritis (RA) is a classic example of
autoimmune disease. Joint inflammation in rheumatoid
arthritis (RA) is characterized by invasion of T cells in the
synovial space and proliferation of activated macrophages
and fibroblasts in the synovial intima [63]. Therefore, in
the rheumatic joint there is an increased activity of fibrob-
lasts and leucocytes which produce ROS [64,65]. Very
recently, antioxidants have been successfully used as adju-Nutrition Journal 2008, 7:29 http://www.nutritionj.com/content/7/1/29
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vant therapy in RA [66,67]. Although the results obtained
with RA seemed to be very promising, the indiscriminate
use of antioxidants in autoimmune disorders is not rec-
ommended. In fact, autoimmune lymphoproliferative
syndrome (ALPS), MS, type 1 diabetes and multiple
autoimmune syndrome, have been linked to decreased
Fas functionality [68] and, as discussed previously, anti-
oxidants may up-regulate Fas and FasL in vitro. Increasing
evidence provides support that oxidative stress and apop-
tosis are closely related physiological phenomena and are
implicated in diseases including autoimmune diseases.
Therefore molecules that target both apoptosis-related sig-
nal transduction and oxidative stress, like antioxidants,
are likely to result in the improvement of these patholo-
gies.
A novel possible approach to modulate immune system
thus preventing autoimmunity or transplant rejection is
the activation of cytoprotective and antioxidant enzymes
such as HO-1. Heme oxygenase-1, the inducible isoform
of HO, is a key protein in the cell stress response and its
up-regulation is a common event during pro-inflamma-
tory conditions [11,69-72]. Recent work clearly demon-
strated that regulatory T cells overexpress HO-1 and
release CO under pro-oxidant conditions. Carbon mon-
oxide may inhibit the proliferation of effector T cells, thus
reducing the immune response and prevent autoimmu-
nity and/or graft reaction [73,74]. Dietary antioxidants, in
particular polyphenols, has been shown to increase HO-1
expression in different in vitro systems [3,75,76] and the
potential use of this natural substances to regulate
immune response should be carefully addressed.
Antioxidants, Cancer And Neurodegenerative Disorders
It is well known that the dietary consumption of fruits,
vegetables, herbs, or their phytochemical constituents aid
in cancer prevention [77-79]. It is believed that the anti-
oxidant properties of such foods protect cells from ROS-
mediated DNA damage that can result in mutation and
subsequent carcinogenesis. ROS-induced DNA damage
can take many forms, ranging from specifically oxidized
purine and pyrimidine bases, to DNA lesions such as
strand breaks, sister chromatid exchanges (SCEs), and the
formation of micronuclei [80]. However, the equation
"antioxidant = benefit" is not always true. In vivo experi-
ments demonstrated that retinol increases both the
humoral and the cell-mediated immune response and
could enhance immune surveillance against tumorigene-
sis [81-83]. Retinol may influence the immune response
by quenching free radicals, which could lower the level of
immunosuppressing lipid peroxides, alter arachidonic
acid metabolism, etc. [82,84]. In the last few years many
studies have been conducted to investigate the effects of
vitamins on disease prevention. The first results have been
encouraging and a wide number of people are taking anti-
oxidant supplements with the aim to improve their
health. These studies, initially, have shown that a high
consumption of fruit and vegetables decreases risks of
lung cancer in healthy individuals and a combination of
β-carotene, vitamin E and selenium reduced stomach can-
cer mortality in China [85,86]. Conversely, supplemental
β-carotene alone or in combination with retinol or vita-
min E did not have any effect on cancer risk, or increased
the development of lung cancer in smokers [87,88]. In the
light of these first contrasting result, and also as a conse-
quence of the wide antioxidant consumption in the gen-
eral population, various systematic reviews to estimate the
association between antioxidant use and disease preven-
tion, in particular for primary cancer incidence and mor-
tality, have been issued. These reviews share the opinion
that antioxidant supplementation per se does not prevent
cancer. On the contrary, some antioxidant elements seem
to be harmful fro health. Recent studies have confirmed
the relationship between beta-carotene and an increased
incidence of cancer among smokers, but not among non-
smokers. Moreover, beta carotene supplementation is
associated with increased cancer-related mortality [89].
Vitamin E treatment also appears to be associated with a
slightly increased incidence of lung cancer [90]. Other
studies report that combination of vitamin A and other
antioxidants, significantly increases mortality related to
neoplastic diseases [91]. According to these studies, sele-
nium would be the only element displaying beneficial
effects, as it has been shown that it reduces total cancer
incidence, an apparently sex-related effect, as it is predom-
inant among males, rather than in females [89].
The reason why β-carotene may exert dual activity, namely
antioxidant or pro-carcinogenic has been debated for
quite a long time. The first hypothesis is that at high con-
centrations, β-carotene stimulates free radical production,
whereas at lower concentrations β-carotene exerts antioxi-
dant activity [90,91]. Furthermore, in the presence of cig-
arette smoke-derived free radicals β-carotene is cleaved
into many derivatives which are very unstable and may
trigger further oxidation [92-95]. A recent corollary to this
theory is the evidence that β-carotene, either alone or in
combination with cigarette smoke condensate, repressed
HO-1 expression both in rat fibroblasts and human lung
cancer cells [96]. The reduced expression of HO-1
accounted for a reduced production of CO and BR both of
which have a marked antiproliferative effects [96-100].
Vitamin E has also been shown to act at the immune sys-
tem level; in fact, supplementation with this vitamin can
increase production of antibodies and enhance cell-medi-
ated immunity in both experimental animals and in
humans [101].
Neurodegenerative diseases, such as Parkinson's disease
(PD), Alzheimer's disease (AD), and amyotrophic lateralNutrition Journal 2008, 7:29 http://www.nutritionj.com/content/7/1/29
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sclerosis (ALS), as well as multiple slerosis (MS), are trig-
gered, at least in part, by oxidative and nitrosative stress
and also sustained by inflammatory cytokine production
[11,70,102-104]. Similarly, autoimmunity mainly con-
tributes to the pathogenesis of MS, characterized by cen-
tral and peripheral loss of nerve myelin [105,106].
Although the specific sources of the damaging ROS and
the affected target structures differ between the neuronal
pathologies, the following general features can be defined.
Increased levels of oxidation-altered metabolites are
found in post-mortem tissues in many of the neurodegen-
erative diseases listed above [107-113]. An oxidative stress
response and compensatory defense reactions can be seen
in the affected neural cells; further, disturbances of the
mitochondrial metabolism are observed, which may
account for an increased leakage of ROS originating from
the respiratory chain [11,70,104,114]. However, in addi-
tion to the direct induction of oxidative stress, metabolic
disorders underlying every single disease can also indi-
rectly generate an oxidative microenvironment, for exam-
ple via the induction of a local immune response
[115,116]. On this basis, antioxidant and antinflamma-
tory drugs, such as polyphenols and non-steroidal antin-
flammatory drugs (NSAIDs), have been proposed in the
treatment of different neurodegenerative diseases [117-
119]. However, both polyphenols and NSAIDs gave rise
to some problems when used in clinical setting. Due to
their scarce bioavailability, only a negligible amount of
polyphenols reaches brain tissue and the concentrations
achieved are much lower than those efficacious in vitro
[3]. As far as NSAIDs, ad hoc designed clinical trials with a
large number of patients, clearly demonstrated that these
drugs do not have any significant effect in slowing cogni-
tive decline in patients suffering from mild-to-moderate
AD [120,121]. Similar disappointing results have been
obtained in the treatment of ALS, a systemic motor neu-
ron disease that affects corticospinal and corticobulbar
tracts, ventral horn motor neurons and motor cranial
nerve nuclei [122,123]. Approximately 10% of cases are
familial and have been linked to point mutation in the
gene encoding for Cu/Zn superoxide dismutase (SOD)
[124]. Mice transgenic for mutated SOD1 develop symp-
toms and pathologies similar to those in human ALS.
Mutant SOD1 toxicity is mediated by damage to mito-
chondria in motor neurons, and this may trigger the func-
tional decline of motor neurons and the onset of ALS in
mice [125]. Unfortunately, although the role played by
free radical to the pathogenesis of ALS has been demon-
strated, antioxidants did not have any effect to prevent or
slow down its progression. Desnuelle et al., clearly dem-
onstrated that alpha-tocopherol, given together with rilu-
zole, did not affect the survival and motor functions in
ALS patients respect to the group treated with riluzole
alone [126]. Novel compound, such as AEOL-10150
(Aeolus), structurally related to the SOD catalytic site, is
under phase I clinical investigation, but further clinical tri-
als will be necessary to evaluate the real efficacy of this
compound for the therapy of ALS [127,128].
Conclusion
The field of antioxidants is moving rapidly. About 20
years ago the hypothesis that diet might have a substantial
influence on the development of some pathologies, such
as cancer, has been raised by many scientists. In this light,
during the last decade, efforts have been made to analyze
the effects of plant food and synthetic antioxidants on the
development and prevention of chronic diseases. Nowa-
days, antioxidants are used on a large scale to try to obtain
and preserve optimal health. While there is no doubt that
the correct balance between endogenous and exogenous
antioxidant capacity is essential to life, the curative power
of antioxidants has often been overestimated. In fact,
according to the popular idea "if one is good two is bet-
ter", antioxidants are taken in excess too often and the risk
to originate diseases instead of preventing them is quite
high. It is noteworthy to underlie that as for all drugs, anti-
oxidants may give important side effects if not correctly
used or in combination with other drugs. Vitamin A, E
and β-carotene for instance, have been shown to have pro-
oxidant effects at higher doses or under certain conditions
[39].
Another point of criticism is the possibility to take exper-
imental results "from the bench to the bedside". In fact,
although the promising results obtained by in vitro exper-
iments, the use of antioxidants in the treatment of human
disease states has not been as successful as might have
been envisaged due to intrinsic pharmacokinetic or phar-
macodynamic limitations.
In addition, conclusions on beneficial effect of antioxi-
dant are often drawn from studies conducted with syn-
thetic antioxidant supplement, whereas fruits and
vegetable are a complex mixture of antioxidant, as well as
other potentially beneficial micronutrients and macronu-
trients, which may, thus, work with different kinetics and
dynamics [89].
In conclusion, the correct use of antioxidants may be use-
ful to prevent free radical-related disorders. However, the
repair of existing critical structural damage may be beyond
the possibilities of antioxidants and therefore they may
not be considered to be useful in therapeutic clinical
applications, where their limits and eventual side effects
must be better understood.
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